Mitchell Horwitz, MD

The professor of medicine at Duke Cancer Institute discussed uptake and research with the cord blood therapy since its approval.

The professor of medicine at Duke Cancer Institute discussed findings from an early access program of the therapy, recently approved as Omisirge.